

In re Application of:  
Fernandez et al.  
Application No.: 09/990,091  
Filed: November 21, 2001  
Page 2

PATENT  
Atty. Docket No.: INVIT1120-3

I. AMENDMENTS

Please cancel claims 52, 53, 58, 67, and 70 without prejudice.

*C Sub 1*  
Please amend claim 76 to read as follows:

76. (Currently amended) The method of claim 71, wherein the expression vectors are suitable for prokaryotic expression and eukaryotic expression.

*C 2*  
Please add the following new claims.

--77. (New) A method for producing a library of selected expressible open reading frames (ORFs), the method comprising:

a) amplifying deoxyribonucleic acid (DNA) molecules comprising a plurality of ORFs using a primer pair, wherein the primer pair comprises a 5' primer, which comprises a nucleotide sequences starting 5'-CACCATG, and a 3' primer, which causes the amplification product to end just prior to a stop codon, thereby producing a plurality of amplified ORFs;

b) inserting amplified ORFs of the plurality into expression vectors using a vaccinia DNA topoisomerase, thereby producing expression vectors comprising the *-Cp. w/*,  
amplified ORFs;

c) transforming cells with the expression vectors comprising the amplified ORFs; and

d) selecting transformed cells containing expression vectors comprising ORFs in an orientation for expression of a polypeptide encoded by the ORF.

78. (New) The method of claim 77, wherein inserting the amplified ORFs into the expression vectors is performed using an enzyme that cleaves and ligates DNA.

In re Application of:  
Fernandez et al.  
Application No.: 09/990,091  
Filed: November 21, 2001  
Page 3

PATENT  
Atty. Docket No.: INVIT1120-3

79. (New) The method of claim 78, wherein the enzyme is a vaccinia DNA topoisomerase, a lambda integrase, an FLP recombinase, or a P1-Cre protein.

*C2 cont*  
80. (New) The method of claim 77, wherein the expression vectors are suitable for prokaryotic expression and eukaryotic expression.--